Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs October 25, 2023
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Ph 3 Study of Lisaftoclax + Acalabrutinib in 1L CLL/SLL Patients October 25, 2023
Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics October 25, 2023
Elevar Therapeutics & Jiangsu Hengrui Pharma Announce Global Commercialization Licensing Agreement for Camrelizumab + Rivoceranib for uHCC October 25, 2023
Phanes Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate PT886 in Combination with KEYTRUDA October 25, 2023
First Patient Dosed in the Registrational Ph 3 Study of Olverembatinib in 1L Ph+ ALL Patients October 25, 2023
First Patients Dosed in First-in-Human Ph 1 Study of FX-909 in Advanced Solid Tumors, Including Urothelial Cancer October 25, 2023
Ph 3 CheckMate-67T Trial of SC Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced/Metastatic ccRCC October 25, 2023
New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study Released October 25, 2023
Interim PK/PD and Clinical Data for MRT-2359 in Ph 1/2 Trial for MYC-Driven Solid Tumors announced October 25, 2023
Tagrisso plus chemo granted Priority Review in the US for patients with EGFR-mutated advanced NSCLC October 25, 2023
Positive CHMP opinion recommending approval of Jemperli (dostarlimab) + chemo as 1L treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer October 25, 2023
BRUKINSA Receives Positive Recommendation from NICE in U.K. for Adult Patients with CLL October 25, 2023
Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL in the European Union October 25, 2023
Global Registrational Ph 3 Study of Lisaftoclax in 1L CLL/SLL Patients Approved by the China CDE October 25, 2023
FDA Approves KEYTRUDA for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemo as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery October 25, 2023
European Commission Approves KEYTRUDA as Adjuvant Treatment for Adults With NSCLC at High Risk of Recurrence Following Complete Resection & Platinum-Based Chemo October 25, 2023
EC Approves ADCETRIS + AVD combo for Adult Patients with 1L CD30+ Stage III Hodgkin Lymphoma October 25, 2023
FDA Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma October 25, 2023
